Nanobiotix reports Phase 1 results for NBTXR3 in recurrent lung cancer

Biotechnology company Nanobiotix has released the full results from a Phase 1 study evaluating its NBTXR3 therapy in patients with inoperable, recurrent non-small cell lung cancer (NSCLC) eligible for re-irradiation. The study assessed the use of NBTXR3, which is activated by radiotherapy, in combination with re-irradiation.

According to the study, all 24 patients completed treatment without experiencing dose-limiting toxicities related to NBTXR3 or the injection procedure. Investigators deemed the intratumoral injection feasible.

The treatment's efficacy was measured by several metrics. The one-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects. These outcomes were achieved using a lower re-irradiation dose compared to patients' prior radiotherapy course.

Investigators concluded that NBTXR3 may enable clinically meaningful local control at a substantially lower re-irradiation dose. No Grade 3 or higher adverse events related to NBTXR3 or the injection were reported. The study has completed enrollment as per protocol, and further patient enrollment is planned due to the encouraging findings.